My insurance denied Wegovy. Are compounded GLP-1s my best option?

Short answer: usually no — compounded GLP-1s are generally not the best first option. Try appeals and safer, approved alternatives first. Compounded versions carry safety, quality, and insurance/payment risks and are rarely covered.

Why not start with other paths?

• Appeal/coverage review: Many denials can be reversed. Ask your prescriber to submit a prior‑authorization or an appeal (including BMI, weight‑related comorbidities, prior conservative treatments, and a letter of medical necessity). Request a peer‑to‑peer review with the insurer’s medical reviewer.
• Manufacturer help and coupons: Novo Nordisk (Wegovy) and other manufacturers often have savings programs or patient assistance for eligible patients — these can substantially lower out‑of‑pocket cost for commercially insured or uninsured patients.
• Covered therapeutic alternatives: Your insurer may cover other FDA‑approved GLP‑1 or GIP/GLP‑1 drugs (and some are used for weight). Examples:
  • Ozempic (semaglutide) or Rybelsus (oral semaglutide) — approved for diabetes but often covered and can produce weight loss (dosage/label differs from Wegovy).
  • Saxenda (liraglutide) — approved for weight loss (daily injection).
  • Zepbound (tirzepatide) or Mounjaro (tirzepatide for diabetes) — tirzepatide has strong weight‑loss effects; coverage is variable. These options are FDA‑approved products with known manufacturing controls and more predictable safety profiles than compounded drugs.

Problems with compounded GLP‑1s

• Not FDA‑approved: compounded semaglutide/tirzepatide products aren’t subject to the same manufacturing and clinical standards as brand products.
• Quality and sterility risk: batch variability, contamination, wrong concentration, and injection‑device problems have been reported with some unregulated supplies.
• Source of active ingredient uncertain: some compounding pharmacies obtain bulk API from overseas suppliers of uncertain quality.
• Insurance won’t usually pay: compounded products are typically out‑of‑pocket.
• Legal/regulatory risk: buying injectable drugs online or from unverified sources can be dangerous.

When might compounding be considered?

• Only if all approved, covered, and safe options are exhausted, and you and your prescriber accept the risks.
• If you proceed, use a reputable, accredited source: prefer an FDA‑registered 503B outsourcing facility or a compounding pharmacy accredited by the Pharmacy Compounding Accreditation Board (PCAB). Ask the pharmacy for sterility testing, Certificates of Analysis for the API, and cold‑chain handling documentation.

Practical next steps I recommend now

1. Contact your prescriber to:
   • Submit/reevaluate prior authorization and file an appeal with medical necessity documentation.
   • Ask for a peer‑to‑peer review with the insurer’s doctor.
   • Consider switching to an alternative GLP‑1 your plan covers (Ozempic, Rybelsus, Saxenda, or tirzepatide if available).
2. Check manufacturer assistance:
   • Ask about Wegovy savings programs or Novo Nordisk patient assistance; check Lilly’s patient support for tirzepatide products if relevant.
3. Use price‑help tools while you sort coverage: GoodRx or Blink Health can reduce copays for covered, approved brand drugs.
4. Avoid buying injectable compounds online from unknown vendors. If you’re seriously considering compounding, insist on documentation from the pharmacy and discuss risks with your clinician.

If you want, I can:

• Help draft a short appeal/medical necessity letter your clinician can adapt.
• Look up alternative GLP‑1s your insurer might cover (if you tell me the insurer and whether you have Medicare/Medicaid or commercial insurance).
• Help evaluate a specific compounding pharmacy’s credentials if you already have one in mind.